Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (>95% sustained virologic response, SVR) against all genotypes of HCV. Achievement of SVR has been associated with a significant reduction of hepatic decompensation, development of HCC, and liver-related mortality. However, HCC risk is not eliminated even after SVR. The annual incidences of HCC in advanced fibrosis or cirrhosis have been estimated to be up to 2.5–4.5% even in patients with SVR. Therefore, surveillance for HCC is recommended in this high-risk patients. In this review, we will describe the clinical outcomes and the risk of HCC in patients with SVR and suggest who should receive surveillance for HCC.
Citations
Citations to this article as recorded by
Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2024; 39(6): 1155. CrossRef
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy” Seren M. Gedallovich, Paul Y. Kwo Clinical and Molecular Hepatology.2024; 30(4): 1050. CrossRef
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro Viruses.2024; 16(12): 1899. CrossRef
Accurate prediction of HCC risk after SVR in patients with hepatitis C cirrhosis based on longitudinal data Yanzheng Zou, Ming Yue, Linna Jia, Yifan Wang, Hongbo Chen, Amei Zhang, Xueshan Xia, Wei Liu, Rongbin Yu, Sheng Yang, Peng Huang BMC Cancer.2023;[Epub] CrossRef
A scoring system for predicting hepatocellular carcinoma risk in alcoholic cirrhosis Kyunghan Lee, Gwang Hyeon Choi, Eun Sun Jang, Sook-Hyang Jeong, Jin-Wook Kim Scientific Reports.2022;[Epub] CrossRef
Liver CT Perfusion Imaging as a Non-Invasive Method for Assessing Hemodynamics of the Hepatic Parenchyma in Patients with Fibrosis and Cirrhosis as a Result of Chronic Viral Hepatitis C G. A. Stashuk, Ya. G. Moysyuk, D. Ya. Smirnova, O. V. Sumtsova Journal of radiology and nuclear medicine.2022; 102(6): 359. CrossRef
Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review Victoria Green, Marina Roytman, Haruki Komatsu Case Reports in Hepatology.2022; 2022: 1. CrossRef
Hepatocellular Carcinoma-Related Mortality in the USA, 1999–2018 Azaan Ramani, Elliot B. Tapper, Connor Griffin, Nagasri Shankar, Neehar D. Parikh, Sumeet K. Asrani Digestive Diseases and Sciences.2022; 67(8): 4100. CrossRef
Risk of hepatocellular carcinoma in patients with chronic hepatitis c infection and stage 3 fibrosis after sustained virological response Antonio Olveira Martín, María Luisa García Montes, María Sanchez-Azofra Revista Española de Enfermedades Digestivas.2022;[Epub] CrossRef
Hepatocellular carcinoma incidence in chronic hepatitis C patients according to sustained virological response (SVR) with interferon‐based therapies and baseline characteristics Tuul Purevsambuu, Simona Bota, Florian Hucke, Harald Hofer, Peter Ferenci, Wolfgang Sieghart, Markus Peck‐Radosavljevic Liver Cancer International.2022; 3(2): 53. CrossRef
Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years After SVR Yanzheng Zou, Ming Yue, Linna Jia, Yidi Wang, Hongbo Chen, Yifan Wang, Meiling Zhang, Yue Feng, Rongbin Yu, Sheng Yang, Peng Huang Journal of Hepatocellular Carcinoma.2022; Volume 9: 1433. CrossRef
Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan Satoko Ohfuji, Tomoka Matsuura, Akihiro Tamori, Shoji Kubo, Satoshi Sasaki, Kyoko Kondo, Kazuya Ito, Wakaba Fukushima Digestive Diseases and Sciences.2021; 66(6): 2118. CrossRef
N6-methyladenosine modification of HCV RNA genome regulates cap-independent IRES-mediated translation via YTHDC2 recognition Geon-Woo Kim, Aleem Siddiqui Proceedings of the National Academy of Sciences.2021;[Epub] CrossRef
Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C Hala Rady Ahmed, Nancy G. F. M. Waly, Rehab Mahmoud Abd El-Baky, Ramadan Yahia, Helal F. Hetta, Amr M. Elsayed, Reham Ali Ibrahem, Philippe Gallay PLOS ONE.2021; 16(4): e0249770. CrossRef
Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea Jae Seung Lee, Hong Jun Choi, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2021; 36(9): 2479. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Present and future management of viral hepatitis Rocío González Grande, Inmaculada Santaella Leiva, Susana López Ortega, Miguel Jiménez Pérez World Journal of Gastroenterology.2021; 27(47): 8081. CrossRef
Hepatitis C Virus Translation Regulation Michael Niepmann, Gesche K. Gerresheim International Journal of Molecular Sciences.2020; 21(7): 2328. CrossRef
A Survey of Liver Cancer Specialists’ Views on the National Liver Cancer Screening Program in Korea Won Sohn, Young-Sun Lee, Jae Geun Lee, Jihyun An, Eun Sun Jang, Dong Ho Lee, Dong Hyun Sinn Journal of Liver Cancer.2020; 20(1): 53. CrossRef
Two Cases of Hepatocellular Carcinoma Arising Over 20 Years after a Sustained Virologic Response Following Interferon Therapy for Chronic Hepatitis C Kazuhide Takata, Fuminori Ishii, Yotaro Uchida, Hiromi Fukuda, Ryo Yamauchi, Kaoru Umeda, Naoaki Tsuchiya, Takashi Tanaka, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai Internal Medicine.2020; 59(15): 1855. CrossRef
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy Chung-Feng Huang, Ming-Lung Yu Clinical and Molecular Hepatology.2020; 26(3): 251. CrossRef
The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands Mohamed N.M.T. Al Khayat, Job F.H. Eijsink, Maarten J. Postma, Jan C. Wilschut, Marinus van Hulst International Journal of Environmental Research and Public Health.2020; 17(17): 6091. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Andrew S. Chung, Marcel Mettlen, Debolina Ganguly, Tianshi Lu, Tao Wang, Rolf A. Brekken, David Hsiehchen, Hao Zhu Cancer Prevention Research.2020; 13(11): 911. CrossRef
Hepatitis C Virus Downregulates Core Subunits of Oxidative Phosphorylation, Reminiscent of the Warburg Effect in Cancer Cells Gesche K. Gerresheim, Elke Roeb, Audrey M. Michel, Michael Niepmann Cells.2019; 8(11): 1410. CrossRef
First
Prev
